SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Bertram L) ;lar1:(liu)"

Search: WFRF:(Bertram L) > Linköping University

  • Result 1-2 of 2
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  • Becher, Peter Moritz, et al. (author)
  • Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry
  • 2023
  • In: European Heart Journal - Cardiovascular Pharmacotherapy. - : OXFORD UNIV PRESS. - 2055-6837 .- 2055-6845. ; 9:4, s. 343-352
  • Journal article (peer-reviewed)abstract
    • Aims The SOLOIST-WHF trial demonstrated efficacy of sotagliflozin in patients with type 2 diabetes mellitus (T2DM) and recent worsening heart failure (HF) regardless of ejection fraction (EF). Selection criteria in trials may limit their generalizability. Therefore, we aimed to investigate eligibility for sotagliflozin based on the SOLOIST-WHF criteria in a real-world HF population. Methods and results SOLOIST-WHF criteria were applied to patients stabilized after HF hospitalization in the Swedish HF Registry according to (i) literal scenario (all inclusion/exclusion criteria) or (ii) pragmatic scenario (only criteria likely to influence treatment decisions). Of 5453 inpatients with T2DM and recent worsening HF, 51.4% had reduced EF (HFrEF), 19.1% mildly reduced (HFmrEF), and 29.5% preserved EF (HFpEF). Eligibility (literal) was: 27.2% (32.4% in HFrEF, 24.7% in HFmrEF, 19.7% in HFpEF) and eligibility (pragmatic) was 62.8% (69.1%, 60.3%, 53.4%, respectively). In the literal scenario, criteria limiting eligibility were HF duration <3 months, eGFR <30 ml/min/1.73 m(2), age >85 years, acute coronary syndrome <3 months, and insufficiently high N-terminal pro-B-type natriuretic peptide levels. Eligible vs. non-eligible patients had more severe HF, higher cardiovascular (CV) comorbidity burden, higher use of HF treatments, and higher event rates (all-cause death 30.8 vs. 27.2 per 100 patient-years, CV death 19.1 vs. 16.6, and HF hospitalization 36.7 vs. 24.0). Conclusion In this large, real-world HF cohort with T2DM, similar to 1/3 of patients were eligible for sotagliflozin in the literal and similar to 2/3 of patients in the pragmatic scenario. Eligible patients had more severe HF and higher event rates, in particular CV and HF events.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-2 of 2
Type of publication
journal article (2)
Type of content
peer-reviewed (2)
Author/Editor
Bai, Y. (1)
Brown, J. (1)
Chen, C. (1)
Chen, H. (1)
Chen, S. (1)
Francis, D. (1)
show more...
Huang, Y. (1)
Li, B. (1)
Li, H. (1)
Liu, B. (1)
Liu, M. (1)
Liu, Y. (1)
March, L. (1)
Pinder, A. (1)
Sanchez, A. (1)
Silva, J. (1)
Walker, R. (1)
Wang, F. (1)
Wang, J. (1)
Webb, S. (1)
White, S. (1)
Williams, S. (1)
Wilson, A. (1)
Xu, L. (1)
Yang, Y. (1)
Zhang, H. (1)
Zhang, J. (1)
Zhang, L. (1)
Zhu, Y. (1)
Brenner, L. (1)
Simon, D. (1)
Zhou, C. (1)
Brown, G. (1)
Ellis, K. (1)
Rose, A. (1)
Zhao, L. (1)
He, M. (1)
Ryan, P. (1)
Schmitz, M. (1)
Zhao, T. (1)
Gupta, A. (1)
Joseph, J. (1)
Kennedy, J. (1)
Li, J. (1)
Yuan, J. (1)
Zhang, Q. (1)
Ren, Y. (1)
Martin, J. (1)
Ahmad, A. (1)
Alexander, M. (1)
show less...
University
Linköping University  (2)Undo refine
Karolinska Institutet (2)
Language
English (2)
Research subject (UKÄ/SCB)
Medical and Health Sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view